Immunocore Holdings plc

For the period ended Jun 30, 2026. Filed Aug 6, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 6, 2026

IMCR$32.38+2.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Shareholders’ Equity for the

Condensed Consolidated Statements of Shareholders’ Equity

(Unaudited) (In thousands, except share data)

Ordinary Shares · Deferred Shares · Additional Paid-in Capital · Accumulateddeficit · Accumulated other comprehensive (loss) income · Total Shareholders' Equity
Shares · Amount · Shares · Amount
As of December 31, 2025	50,689,271	$136	5,793,501	$1	$1,240,255	$(831,275)	$(28,084)	$381,033
Net income	—	—	—	—	—	12,971	—	12,971
Other comprehensive loss	—	—	—	—	—	—	(7,289)	(7,289)
Equity plan options exercised and units assigned	142,657	1	—	—	655	—	—	656
Share-based compensation expense	—	—	—	—	6,302	—	—	6,302
As of March 31, 2026	50,831,928	$137	5,793,501	$1	$1,247,212	$(818,304)	$(35,373)	$393,673
Net loss	—	—	—	—	—	(808)	—	(808)
Other comprehensive income	—	—	—	—	—	—	1,043	1,043
Equity plan options exercised and units assigned	648,231	1	—	—	16,485	—	—	16,486
Share-based compensation expense	—	—	—	—	9,404	—	—	9,404
As of June 30, 2026	51,480,159	$138	5,793,501	$1	$1,273,101	$(819,112)	$(34,330)	$419,798

Condensed Consolidated Statements of Shareholders’ Equity

(Unaudited) (In thousands, except share data)

Ordinary Shares · Deferred Shares · Additional Paid-in Capital · Accumulateddeficit · Accumulated other comprehensive (loss) income · Total Shareholders' Equity
Shares · Amount · Shares · Amount
As of December 31, 2024	50,064,860	$135		5,793,501		$1		$1,190,104		$(795,761)		$(33,763)		$360,716
Net income	—		—		—		—		—		5,023		—		5,023
Other comprehensive income	—		—		—		—		—		—		673		673
Exercise of share options	119,749		—		—		—		2,551		—		—		2,551
Share-based compensation expense	—		—		—		—		9,516		—		—		9,516
As of March 31, 2025	50,184,609	$135		5,793,501		$1		$1,202,171		$(790,738)		$(33,090)		$378,479
Net loss	—	—		—		—		—		(10,300)		—		(10,300)
Other comprehensive income	—	—		—		—		—		—		6,476		6,476
Exercise of share options	187,459	—		—		—		3,670		—		—		3,670
Share-based compensation expense	—	—		—		—		10,156		—		—		10,156
As of June 30, 2025	50,372,068	$135		5,793,501		$1		$1,215,997		$(801,038)		$(26,614)		$388,481

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.